There are presently over 12,000 clinical trials being conducted in the United States, funded by government, educational, and private industry sources. These studies commonly employ vital signs monitoring to study a wide variety of abnormal human health conditions or the pharmacological effects of drugs not yet approved for the market.

It is estimated that of the 12,000 studies currently recruiting subjects, approximately 4,000 could directly benefit from the expanded vital-signs parameters and increased information-gathering capability of the Sensatex System. In addition, we believe that the advantages of portability and ease of use offered by the Sensatex System will expand the range of studies that can be conducted. Research hindered by exorbitant monitoring costs could be made more feasible with the introduction of the Sensatex System.